ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Clinical Outcomes of Mitral Valve Surgery in Atrial Functional Mitral Regurgitation in the REVEAL-AFMR Registry

Thursday, November 21, 2024

Submitted by

Mateo Marin-Cuartas

Source

Source Name: JAMA Network

Source URL: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822409

Author(s)

Nobuyuki Kagiyama, Tomohiro Kaneko, Masashi Amano, Yukio Sato, Yohei Ohno, Masaru Obokata, Kimi Sato, Taiji Okada, Naoki Hoshino, Kentaro Yamashita, Yuko Katsuta, Yuki Izumi, Mitsuhiko Ota, Yasuhide Mochizuki, Kaoruko Sengoku, Shunsuke Sasaki, Fukuko Nagura, Nanaka Nomura, Ryo Nishikawa, Nahoko Kato, Takahiro Sakamoto, Noriko Eguchi, Maiko Senoo, Mariko Kitano, Yoichi Takaya, Yoshihito Saijo, Hidekazu Tanaka, Kotaro Nochioka, Nami Omori, Minoru Tabata, Tohru Minamino, Naoki Hirose, Kojiro Morita, Tomoko Machino-Ohtsuka, Victoria Delgado, Yukio Abe

This cohort study, called the Real-World Observational Study for Investigating the Prevalence and Therapeutic Options for Atrial Functional Mitral Regurgitation (REVEAL-AFMR), aimed to investigate the prevalence, clinical characteristics, and outcomes of mitral valve (MV) surgery in atrial functional mitral regurgitation (AFMR). The study was conducted across 26 Japanese centers, reviewing all transthoracic echocardiograms performed between January and December 2019 to enroll adult patients with moderate or severe AFMR. Patients who underwent MV surgery, with or without tricuspid valve surgery, were compared to those who did not undergo surgery. The primary outcome was a composite of heart failure hospitalization and all-cause mortality.

Among 177,235 patients who underwent echocardiography, a total of 8,867 had moderate or severe MR. Within this group, 1,007 (11.4 percent) were diagnosed with AFMR (mean [SD] age, 77.8 [9.5] years; 55.7 percent female), and 807 (80.1 percent) had atrial fibrillation. Of these patients, 113 underwent MV surgery, with 92 (81.4 percent) receiving concurrent tricuspid valve surgery. Despite a more severe disease status, only the surgical group showed a decrease in natriuretic peptide levels at follow-up and had a significantly lower rate of the primary outcome (three-year event rates were 18.3 percent versus 33.3 percent; log-rank P = .03). Statistical adjustments did not alter these findings. The authors conclude that in patients with AFMR, MV surgery was associated with lower rates of adverse clinical outcomes.